Postdoctoral Position(s) Available in Dou Lab
There is an exciting new opportunity at the University of Southern California for highly motivated postdoctoral candidate(s) committed to developing a successful career in chromatin biology or stem cell biology. Our lab has extensive expertise and excellent track record in studying epigenetic regulations of cell fate determination using embryonic stem cell, or cancer cell as the model. We employ multidisciplinary approaches to understand the functions of histone modifying enzymes in a variety of physiological and pathological processes.
Responsibilities include a) Developing novel approaches to characterize epigenomes in stem cells and cancer cells, b) Conducting cellular, molecular and in vivo experiments for hypothesis-driven research, and c) Preparing presentations and publishing scientific manuscripts under the direction of the Principal Investigator. Candidate will enjoy a highly collaborative environment in Dou lab as well as USC research community. It is essential that the applicant has excellent organizational and communication skills. The postdoctoral trainees will be encouraged to submit their own fellowship and grant applications during their periods of training.
Applicants should hold a PhD or be close to the completion of a PhD. Degree in Molecular and Cellular Biology, Genetics, Developmental Biology, or in a relevant field. Experience with standard molecular and cellular biology techniques and familiarity with genomic technologies are essential. Experience in performing epigenomic assays (CRISPR/Cas9, ChIP-, ATAC-, 4C-seq) will be a plus but not required. The ability to learn new techniques quickly and a strict attention to details of experimental protocols are required.
Interested candidates should send a CV to Dr. Dou (yalidou@usc.edu), Professor of Medicine and Co-leader of the Genomic and Epigenomic Regulation Program in the USC/Norris Comprehensive Cancer Center.
Representative publications (2018-2021):
Histone acetyltransferase MOF regulates quiescence in ground-state pluripotency through fatty acid oxidation. Cell Stem Cell, 27(3):441-458, 2020.
Cryo-EM structure of the human Mixed Lineage Leukemia-1 complex bound to the nucleosome. Nature Communication, 10(1):5540. doi: 10.1038/s41467-019-13550-2, 2019.
Facile target validation in an animal model using monobodies. Nature Chemical Biology, 14(9), 895-900, 2018.
HOXA9 reprograms the enhancer landscape during leukemic transformation. Cancer Cell, 34, 643-658, 2018.
